



October 29, 2014

Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014

NEWARK, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release third quarter 2014 financial results on Wednesday, November 12, 2014 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and clinical update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID:21254731; or from the webcast link in the investor relations section of the Company's website at: www.revance.com.

A replay of the call will be available beginning November 12, 2014 at 4:30pm PT/7:30pm ET through midnight on November 13, 2014. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 21254731. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. Revance is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing aesthetic and therapeutic botulinum toxin market. Revance's proprietary TransMTS® technology enables transcutaneous delivery of botulinum toxin A, eliminating the need for injections. Revance's lead product candidate, RT001, is a topical formulation of botulinum toxin type A, which has the potential to be the first commercially-available non-injectable dose form. RT001 is being evaluated in a broad clinical program that includes aesthetic indications such as crow's feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating) and migraine headache. Revance's second product candidate is RT002, a novel injectable formulation of botulinum toxin type A designed to be more targeted and longer lasting than currently available botulinum toxin injectable products.

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

For more information, please visit: www.revance.com.

CONTACT: Westwicke Partners

Leigh Salvo

(415) 513-1281

leigh.salvo@westwicke.com